Kenvue
KVUE NYSE· Personal Care Products
Last close · Oct 26, 2026
$19.50
KIRA · Stoqly’s AI analyst, in plain words
- Kenvue had $15.1B of revenue in fiscal 2025, down 2.1% on the year before.
- Its operating margin was 16.0%, up 4.1 pts: of every 100 in sales, about 16 is left after running the business.
- Kenvue made $1.5B of net profit in fiscal 2025. From fiscal 2021 to 2025, diluted EPS grew −11.0% a year.
- Free cash flow was $1.7B in fiscal 2025, 11.4% of revenue.
- Kenvue returned $1.8B to shareholders in fiscal 2025, 103% of free cash flow. The diluted share count rose 0.1%.
- Kenvue owes $7.5B more than it holds in cash, about 2.5 years of operating profit.
Market cap
$37.5B
P/E
22.4x
Revenue
$15.1B
Net income
$1.5B
Free cash flow
$1.7B
Operating margin
16.0%
Kenvue in 30 seconds · fiscal 2025
Are sales growing?
−2.1%
No. Sales fell 2.1% last year.
Does it make a profit?
9.7%
A little. It keeps 9.7% of every sale as profit.
Does profit turn into cash?
11.4%
Yes. 11.4% of sales ends up as free cash.
Is debt under control?
2.5x
Keep an eye on it. Repaying its debt would take 2.5 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
22.4x
One share costs 22.4 times its yearly profit per share. Typical for its sector: 24.7x.
What Kenvue does
Kenvue sells consumer health products. Its brands include Tylenol and Zyrtec, Listerine, Neutrogena, Aveeno, Johnson's, Band-Aid and Nicorette. Its portfolio has three product groups: Self Care, Skin Health and Beauty, and Essential Health. Its products are marketed in more than 165 countries across North America, Asia Pacific, Europe, the Middle East and Africa, and Latin America. Kenvue earns its revenue by selling these products. Net sales were $15.1 billion in fiscal 2025. Kenvue says it is the world's largest pure-play consumer health company by revenue, and that it focuses only on consumer health. It says it competes in highly competitive markets, and that it depends increasingly on key retailers, e-commerce and other new retail channels. Kenvue was part of Johnson & Johnson (J&J). J&J transferred its consumer health business to Kenvue in April 2023, and Kenvue sold shares to the public in an initial public offering in May 2023.
Biggest risks, in its own words
- The Kimberly-Clark deal may not close, may be delayed, or may not deliver the benefits expected.
- Damage to its brands or reputation, and strong competition in its product markets.
- Not keeping up with changing consumer preferences, or marketing that fails to work.
- Reliance on third parties, including manufacturers, and disruptions at its own or suppliers' plants.
- Fiscal year ends
- December 28, 2025
- Latest annual report
- 10-K · Feb 20, 2026
- Legal name
- Kenvue Inc.
- CIK
- 0001944048
Kenvue · KVUE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $15.1B | $15.0B | $15.4B | $15.5B | $15.1B |
| Revenue growth | — | −0.7% | 3.3% | 0.1% | −2.1% |
| Gross margin | 55.9% | 55.4% | 56.0% | 58.0% | 58.1% |
| Operating margin | 19.4% | 17.9% | 16.3% | 11.9% | 16.0% |
| Net income | $2.1B | $2.1B | $1.7B | $1.0B | $1.5B |
| Net margin | 13.8% | 13.8% | 10.8% | 6.7% | 9.7% |
| Diluted EPS | $1.21 | $1.20 | $0.90 | $0.54 | $0.76 |
| Cash | |||||
| Cash from operations | $334M | $2.5B | $3.2B | $1.8B | $2.2B |
| Capital expenditure | $295M | $375M | $469M | $434M | $475M |
| Free cash flow | $39.0M | $2.2B | $2.7B | $1.3B | $1.7B |
| FCF margin | 0.3% | 14.4% | 17.5% | 8.6% | 11.4% |
| Dividends paid | $0.0M | $0.0M | $766M | $1.6B | $1.6B |
| Share buybacks | $0.0M | $0.0M | $7.0M | $235M | $197M |
| Share count change | — | −0.0% | 7.8% | 4.0% | 0.1% |
| Debt and strength | |||||
| Cash and short-term investments | $740M | $1.2B | $1.4B | $1.1B | $1.1B |
| Debt incl. finance leases | — | $0.0M | $8.3B | $8.6B | $8.5B |
| Shareholders' equity | $20.5B | $20.0B | $11.2B | $9.7B | $10.8B |
| Net debt / EBITDA | — | −0.4x | 2.2x | 3.1x | 2.5x |
| Current ratio | — | 1.5x | 1.1x | 1.0x | 1.0x |
| Interest coverage | — | — | 10.1x | 4.3x | 5.6x |
| Returns and quality | |||||
| Return on capital | — | — | 10.4% | 7.6% | 10.0% |
| Return on equity | — | — | 10.7% | 9.9% | 14.4% |
| Piotroski F-score | — | — | — | 4 | 6 |
| Altman Z'' | — | 4.0 | 1.5 | 1.1 | 1.2 |
Insiders bought, 12 months
$111M
1 insider
Insiders sold, 12 months
$0.7M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kenvue · KVUE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Kenvue KVUE | $37.5B | −2.1% | 16.0% | 11.4% | 10.0% | 22.4x | 6 |
| Estée Lauder Companies EL | $39.7B | 5.1% | 5.2% | 8.7% | 4.9% | — | 6 |
| Coty COTY | $2.8B | −1.5% | −1.4% | 6.0% | −1.0% | — | 3 |
| Procter & Gamble PG | $385.0B | 3.3% | 22.7% | 17.4% | 20.1% | 24.1x | 6 |
| e.l.f. Beauty ELF | $6.8B | 24.6% | 4.5% | 11.6% | 3.8% | 114.2x | 4 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $19.50 a share, the company is worth $37.5B: 22.4 times its earnings of the last four quarters.
Kenvue grew sales faster than 0 of its 4 similar companies. Its P/E is higher than 0 of 2.
Source: SEC EDGAR XBRL filings (CIK 0001944048). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.